top of page

Johnson & Johnson to Shut Down Brisbane Research Facility in a Strategic Shift

Healthcare conglomerate Johnson & Johnson has announced the impending closure of its substantial research and development site in Brisbane, California, a move coming less than two years following the facility's inauguration. The decision was first brought to light by Fierce Biotech and later confirmed by Johnson & Johnson itself.

In a strategic pivot, Johnson & Johnson revealed plans to replace the closing site with a new innovation hub, details of which remain under wraps. Further communication with the San Francisco Business Times unveiled that this new endeavor, dubbed the California Innovation Center, will be situated in an unspecified location within the Bay Area, continuing the company's commitment to fostering scientific advancement in the region.

This development unfolds against the backdrop of a broader industry trend, where the initial surge in pharmaceutical research investment, spurred by the pandemic, appears to be waning. According to Bisnow, the pharmaceutical sector, which saw significant growth during the health crisis, is now experiencing a phase of introspection and realignment, with companies reassessing their expenditures, streamlining their workforce, and reorganizing operations in response to a decelerating investment landscape.

The San Francisco Bay Campus of Johnson & Johnson, which commenced operations in the fall of 2022, was a pivotal expansion aimed at bolstering the company's R&D footprint in Northern California. Designed to accommodate as many as 400 staff members, the facility was a hub for pioneering research in various domains, including gene and RNA therapies, innovative solutions for retinal and infectious diseases, and the integration of artificial intelligence and machine learning in medical research.

Despite the closure of the Brisbane site, Johnson & Johnson maintains its research endeavors in the Bay Area with its South San Francisco facility remaining operational and unaffected by the recent developments. This ongoing presence signifies the company's sustained investment in and commitment to life sciences and technological innovation within the region.


bottom of page